XBI News 130.37 04/24/2014 06:16:54 SPDR S&P Biotech (XBI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 130.37 $XBI

Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.

1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...

After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...

SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.

Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.

Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?

After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.

SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.

3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.

10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.

SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Cracks Beneath the Market's Surface
at The Street - Tue Mar 25, 10:45AM CDT
Even though the market has hit new highs, weakness lurks below. What should you do as an investor?

'Fast Money' Recap: The Value of 'Old Tech' Stocks
at The Street - Tue Mar 25, 4:00AM CDT
The trading panel discussed why these stocks have solid upside momentum and reasonable valuations.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 83

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 211

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 252

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 197

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 30

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 16

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 50

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading

Top 5 Most Recently Viewed Articles

RAMM Pharma Corp. Strategizes Potential Sale of Canapar

Updated Category News Views 184

RAMM Pharma Corp. Explores Strategic Sale Options RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry....

Continue Reading
Marquis Software Solutions Faces Major Data Breach Issues

Updated Category News Views 206

Marquis Software Solutions Faces Data Breach Concerns Recently, Marquis Software Solutions, a notable software and services provider, faced a serious incident regarding a data breach that may have compromised the personal information of many individuals. This breach raised significant concerns for anyone whose data might have been affected. Details of the Cybersecurity...

Continue Reading
Recovering Losses: GSK Securities Class Action Explained

Updated Category News Views 192

Understanding the GSK Securities Class Action Lawsuit Investors in GSK plc (NYSE: GSK) now find themselves presented with a significant opportunity to participate in a class action lawsuit. This legal action is initiated on behalf of purchasers of American Depositary Receipts (ADRs) from a defined Class Period. The relevant dates for this lawsuit span from early in 2020...

Continue Reading
CYPFER and Michael Bay Team Up for Cybersecurity Advancements

Updated Category News Views 366

Strengthening Cybersecurity in Entertainment with CYPFER In an era where digital security is paramount, CYPFER is leading the charge to develop comprehensive cybersecurity strategies tailored for the film and entertainment industry. The company has formed a partnership with iconic filmmaker Michael Bay, known for his blockbuster hits that captivate audiences worldwide....

Continue Reading
Chris Hall Appointed as CPO of IRIS Software Group

Updated Category News Views 108

Chris Hall Steps in as Chief Product Officer at IRIS Software Group Pivotal leadership appointment will accelerate product innovation and delivery of AI-first strategy IRIS Software Group, a renowned global provider of accounting, HR, payroll, and education software, has announced a significant enhancement to its leadership team with the appointment of Chris Hall as Chief...

Continue Reading